On 10/20, Travelers reported a Q3 EPS of $3.12, beating estimates of $2.99. Positives for the quarter were improving margins, core return on equity of 13.5% and continued strong pricing gains in business and personal insurance lines. Paradoxically, COVID-19 has improved profitability due to fewer claims in auto.
Travelers is a high quality, disciplined underwriter of insurance that is focused on returning capital to shareholders through dividends and share buybacks.
Current Price: $123.92 Price Target: $135 (raised from $120)
Position Size: 1.66% TTM Performance: -2.58% (up 14% since 9/30)
Thesis Intact. Key takeaways from the quarter:
- Core business results were solid, beating estimates
· Combined ratio improved 6.6 points to 94.9%, ex-cats it improved 2.6 points to 91.5%
· Net premiums increased 3%
· Strong pricing with renewal premiums up:
- Business +6.3%
- Bond & specialty +8.1%
- Personal Insurance +8.2%
- International +7.3%
· The industry has faced several headwinds – higher cat losses, negative tort trends and falling yields. As a result industry wide pricing has been strongest in 10 years.
· Losses related to COVID-19 total $133m driven primarily by worker’s compensation. These loses were more than offset by lower claims in auto. Net impact of COVID-19 has been a positive 2% points to the combined ratio.
- Net Investment Income rose $38m due to strong returns in private equity investments.
- Strong financial position
- Debt to capital ratio of 22.7%
- Most of debt is long term – just issued a 30yr bond yielding 2.5%
- 97.9% of fixed income portfolio is investment grade with average rating of AA
- Strong rankings from rating agency relative to peers
- TRV yields 2.7%.
- No share buyback due to pandemic. TRV has built roughly $800m in excess capital.
- Prior to pandemic, TRV has long record of returning capital to shareholders – past 10 years shares outstanding have fallen 53%!
- Management has a history of employing capital wisely! Instead of investing in mature business with spotty pricing, they are returning excess capital to shareholders
- Current valuation of 12.2 P/E is close to historical mean. Price target represents 13x 2021’s estimated earnings.
The Thesis on TRV:
- We expect TRV will be able to grow book value per share in the mid-single digits over the near-medium term, and generate ROE in the 10-14% range
- Industry leader with disciplined underwriting and investment portfolio track record
- Consistent returns in the low to mid double digits
- Responsible capital allocation and proven desire to act in the best interests of shareholders
Please let me know if you have any questions.
Thanks,
John
$TRV.us